The effect of combination anti-retroviral therapy regimens on HIV-1 proviral DNA levels in peripheral blood mononuclear cells was examined in 12 HIV-1-positive patients, using endpoint dilution polymerase chain reaction and serial cloning, and sequencing of the gag region of HIV-1. The major clone was defined as the most numerous of 10 analysed clones, and observation periods ranged from 8 months to 32 months (mean 19.7 ± 10.2 months). In five patients (one with primary-stage HIV-1 infection) receiving three anti-retroviral drugs, HIV-1 RNA reduced to undetectable levels (i.e. ≤ 100 copies/ml). HIV-1 proviral DNA and the number of major clones reduced in four of these patients. HIV-1 RNA levels reduced, but remained detectable, in five other patients. In the two remaining patients (both receiving two rather than three anti-retroviral drugs), HIV-1 RNA levels increased. These results suggest that the population of major clones may be affected when HIV-1 RNA levels reduce following combination regimens of anti-retroviral therapy.
Introduction
Highly active anti-retroviral therapy (HAART) has been used to treat people with HIV-1 infection since 1996 in Japan, and there has been tremendous improvement in the prognosis of these patients as a result.
Virological markers of serum HIV-1 RNA levels are related to disease prognosis, and reflect ongoing viral replication. 1 Using HAART, suppression of plasma viral load in HIV-1 infection to undetectable levels (i.e. ≤ 100 copies/ml) has been successful in most patients. Initially it was thought that 2 or 3 years of fully suppressive therapy would achieve elimination of latent infection in resting CD4 T lymphocytes. 2 HAART is effective at suppressing the HIV-1 plasma virion, but it is now estimated that eradication of latent virus from resting CD4 T lymphocytes requires up to 70 years' therapy. 3 Discontinuing HAART causes a rebound of HIV-1 plasma viraemia 4 and viral replication may remain ongoing in I Ariyama, Y Chong, M Murata et al. The effectiveness of HIV-1 anti-retroviral therapy HIV-1-positive patients receiving HAART because of persistent latent HIV-1 infection in resting CD4 T lymphocytes. 5 -7 There are several reports of HIV-1 proviral DNA in patients receiving suppressive antiretroviral therapy, 5 -8 and following combination anti-retroviral regimens, HIV-1 proviral DNA levels in patients with chronic HIV-1 infection have been found to reduce. 7, 8 The present study was undertaken to clarify how proviral DNA in peripheral blood mononuclear cells (PBMCs) is affected by anti-retroviral therapy, and to establish whether it provides clinicians with a mechanism for judging the success of treatment in HIV-1-positive patients in whom HIV-1 RNA levels have become 'undetectable'. We examined serum HIV-1 RNA and HIV-1 proviral DNA levels, and the characteristics of HIV-1 proviral DNA, in PBMCs taken from HIV-1-positive patients receiving potent anti-retroviral therapy.
Patients and methods

PATIENTS
Study participants were HIV-1-positive individuals, classified according to the 1993 guidelines of the Centers for Disease Control (CDC) (patients in whom CD4 count was < 500/ml or HIV-1 RNA level was > 10 000 copies/ml), 9 who were scheduled to receive anti-retroviral therapy at the Department of General Medicine of Kyushu University Hospital, Fukuoka, Japan. The entry point was the first visit to this hospital, the earliest date being January 1997, and the endpoint was March 2001 or end of observation. Patients did not have an opportunistic infection or tumour at entry.
Blood samples were taken from each patient at baseline and monthly thereafter for HIV-1 RNA measurement, and serum samples were separated and stored at -20°C until testing. Mononuclear cells were separated from peripheral blood each month, using the method described by Hirata et al., 10 and stored at -80°C. Clone sequencing was undertaken at baseline and at 3-monthly intervals.
Written, informed consent was obtained from all patients and guidelines for human experimentation set up by our institution were followed.
TREATMENT
Throughout the study, patients were offered anti-retroviral and prophylactic therapies for opportunistic infections. Patients were permitted to take trimethoprim/sulfamethoxazole for Pneumocystis carinii pneumonia and clarithromycin for Mycobacterium avium complex. The effects of these prophylactic therapies on other drugs used to treat HIV infection are not well documented, although we know of no adverse effects.
Each patient was also scheduled to receive anti-retroviral therapy in an open regimen, with two reverse transcriptase inhibitors (zidovudine and lamivudine) and one protease inhibitor, indinavir before 1997, and after it became available in Japan in 1998, nelfinavir. This treatment regimen is commonly used in Japan, and few side-effects have been reported in Japanese patients on this combination (and according to the HIVrelated Drugs Co-operation Research Group in Japan, if side-effects are reported in patients on this regimen, they are often easier to control than the effects of other drug combinations). People who were unable to tolerate our preferred regimen, or who could not take it for economic reasons, were permitted to use other anti-retroviral drug combinations involving either zidovudine plus lamivudine, or didanosine plus saquinavir or stavudine.
The treatment regimens were explained in detail to each patient, and therapeutic compliance was assessed during the trial by 
HIV-1 RNA LEVELS
Particle-associated HIV-1 RNA levels in sera were determined by the Amplicor HIV-1 Monitor assay (Roche Diagnostic Systems, Branchburg, NJ, USA). The negative and positive controls used were those provided with the kit, and the lower limit of detection was 400 copies/ml. If HIV-1 RNA levels detected were ≤ 500 copies/ml, samples were re-examined with the Amplicor HIV-1 Monitor test (detection limit 50 copies/ml).
DNA EXTRACTION AND DETECTION
Genomic DNA was extracted from 1 × 10 6 PBMCs using the DNA Extractor WB Kit (Wako, Osaka, Japan) following the manufacturer's instructions. HIV-1 DNA was detected by nested polymerase chain reaction (PCR) using primers from the gag region of the HIV-1 genome 11 5′-GTAATACCCATGTTYTCAGC-3′ (sense primer) and 5′-AGGGTACTAGTAGTTCCTGC-3′ (antisense) in the first stage, and 5′-TCAGCATTATCAGAAGGAGC-3′ (sense primer) and 5′-ATGTCACTTCCCCTTGGTTC-3′ (antisense) in the second stage.
HIV-1 proviral DNA levels were measured by endpoint dilution PCR 12 and compared with β-globin levels, which acted as controls. HIV-1 proviral DNA titres were expressed as the number of copies/1 × 10 6 PBMCs.
SEQUENCING
We selected the second PCR products (191-bp) in each patient, determined by PCR using primers from each region. These products were subcloned into pT7Blue T-Vectors (Novaten, CA, USA). Ten independent clones of target size were isolated from each serum sample and 600 clones were sequenced using the dideoxynucleotide method 13 with an ABI PRISM™ 310 genetic analyser (PE Applied Biosystems, CA, USA).
STATISTICAL ANALYSIS
HIV-1 proviral DNA and HIV-1 RNA levels were transformed to log (base 10) values before analysis. Kruskal-Wallis one-way ANOVA was used to determine statistical significance; variables were expressed as mean ± SD and P-values ≤ 0.05 were considered statistically significant.
Results
Twelve HIV-1-positive patients provided evaluable data for analysis in the trial, and their clinical characteristics are outlined in Table 1 . All patients were followed for ≥ 8 months, some continued for 32 months (mean 19.7 ± 10.2 months), whereas others discontinued due to non-attendance after ≥ 8 months' follow-up. Patient 12 was in the primary, acute stage of HIV-1 infection. No patient had received HAART before entering this study, although one had taken antiretroviral drugs previously. A further three patients were lost to follow-up. All patients started on the three-drug combination regimen involving two reverse transcriptase inhibitors plus one protease inhibitor, and eight patients remained on this regimen for the follow-up period. Four patients who could not continue this regimen because of severe nausea were switched to regimens where two reverse transcriptase inhibitors or one reverse transcriptase inhibitor and one protease inhibitor were used. One other patient discontinued the three-drug regimen due to economic difficulties after 8 months but was eligible for inclusion in the study. Therapeutic adherence was approximately 80% across the 12 patients described in this paper. 
RNA, DNA AND CD4 T LYMPHOCYTES
At baseline, the median serum HIV-1 RNA level was 102 928 ± 169 207 copies/ml (range 631 -501 187 copies/ml) and the median CD4 T lymphocyte count was 224.9 ± 185.1 cells/µl (range 22 -656 cells/µl).
HIV-1 proviral DNA levels were measured by PCR in 119 blood samples and the lowest measurable HIV-1 proviral DNA titre was 100 copies/1 × 10 6 PBMCs. The HIV-1 proviral DNA levels correlated significantly with serum HIV-1 RNA levels and CD4 T lymphocyte counts ( Fig. 1 ). Strong positive correlations were observed between HIV-1 proviral DNA levels in PBMCs and serum HIV-1 RNA levels (Fig. 1A) , whereas HIV-1 proviral DNA levels in PBMCs (Fig. 1B) and serum HIV-1 RNA levels (Fig. 1C ) had strong negative correlations with CD4 T lymphocyte counts. Table 2 shows the correlations between changes in serum HIV-1 RNA and HIV-1 proviral DNA levels in PBMCs, and the number of major clones in the gag region of the HIV-1 genome for each patient. Only one patient (patient 11) had received antiviral treatment before the study. Serum HIV-1 RNA levels became undetectable in five patients within 6 months of commencing the combination regimen of anti-retrovirals, and the levels remain undetectable. Reductions in serum HIV-1 RNA levels occurred in patients 5 -9, but levels did not become undetectable. Increases in HIV-1 RNA levels were observed in patients 10 and 11 over the study period.
HIV-1 proviral DNA levels in PBMCs were compared at entry and endpoint ( Table 2) and levels reduced in six patients after 9 months' therapy; patients 1 and 4 had reductions over 1 log copies/1 × 10 6 PBMCs.
After 7 months' therapy, HIV-1 proviral DNA levels reduced from 5 copies/1 × 10 6 PBMCs to 2.5 copies/1 × 10 6 PBMCs in patient 12
(who had primary HIV-1 infection). Analysis of PBMCs from patients 6 -8, 10 and 11 showed no significant HIV-1 proviral DNA reduction during the study period.
AMINO-ACID VARIATION
Amino-acid variation was calculated for all patients to examine the diversity of the gag region. The percentage of amino-acid substitution in the HIV-1 gag gene was determined by dividing the total number of mutations by the total number of amino acids, and the average amino-acid variation was 1.35 ± 1.29% (0.20 -4.76%). Patients 1 -4, who had a reduction in the HIV-1 proviral DNA level in PBMCs, had high rates of amino-acid variation. Patient 8 (who was also receiving interferon-β therapy for hepatitis C virus infection) had the highest amino-acid variation, and a reduction of HIV-1 proviral DNA levels in PBMCs was observed in this patient while on interferon therapy. Patients who had no reductions in HIV-1 proviral DNA levels in PBMCs had few variations in amino-acid levels. Figure 2 shows the amino-acid sequences of the gag region in three patients who had population changes of clones in the gag region during the observation period. A consensus sequence for each patient was calculated from 10 deduced amino-acid sequences. These were compared, and the most numerous of the 10 clones analysed was considered to be the major clone. The quantity of the major clone P1-A decreased from entry to endpoint in patient 1 ( Fig. 2A) , whereas the quantity of the major clone P6-A increased from entry to endpoint in patient 6 (Fig. 2B) . In the patient with acute HIV-1 infection, the quantity of major clone P12-A increased across the study period (Fig. 2C ). 
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CLINICAL COURSE
The clinical course of three patients with HIV-1 infection is shown in Fig. 3 , which lists the results of serial CD4 T lymphocyte counts, serum HIV-1 RNA and proviral DNA levels in PBMCs, and sequence analyses of the HIV-1 gag regions of each of the 10 clones. The three patients described in Fig. 3 were receiving the combined regimen of two reverse transcriptase inhibitors and one protease inhibitor. In patient 1, the HIV-1 proviral DNA level reduced from 4.5 log copies/1 × 10 6 PBMCs to 3 log copies/1 × 10 6 PBMCs, and the major clone number reduced from 8 to 5. Patient 6 had a notable reduction in serum HIV-1 RNA level after treatment initiation, but serum HIV-1 RNA level did not become undetectable and the HIV-1 proviral DNA level in PBMCs changed, but not significantly. In this patient, the major clone number increased from 6 to 9 after 10 months' treatment and did not change when serum HIV-1 RNA stabilized. Quasispecies did not significantly change in the chronic HIV-1 patients.
Significant reductions in serum HIV-1 RNA and proviral DNA levels were observed in patient 12, who had acute HIV-1 infection: serum HIV-1 RNA level reduced from 501 187 copies/ml to undetectable, HIV-1 proviral DNA level reduced from 100 000 copies/ 1 × 10 6 PBMCs to 340 copies/1 × 10 6 PBMCs, and the major clone number increased from 7 to 9 (P = 0.004). 
Discussion
The HIV-1 proviral DNA levels in patients with chronic HIV-1 infection are reported to reduce significantly, to 1 log copies, following therapy with two reverse transcriptase inhibitors plus a protease inhibitor (60 -163 weeks' therapy). 7, 8 In four of our chronically infected patients, in whom HIV-1 RNA was reduced to undetectable levels following anti-retroviral therapy, there were notable reductions in HIV-1 proviral DNA. The HIV-1 proviral DNA levels in the remaining patients with chronic HIV-1 infection showed no such dramatic change, compared with the changes observed in serum HIV-1 RNA.
HIV-1 infects activated CD4 T lymphocytes, and the amount of HIV-1 virion produced and released into the extracellular fluid is at least 10.3 × 10 9 particles/day. 14 The HIV-1 proviral DNA level reduction is reported to have two phases: 2 phase 1 is marked by a reduction in the number of CD4 T lymphocytes infected productively, whereas phase 2 has a reduction of resting CD4 T lymphocytes. The HIV-1 proviral DNA levels changed significantly in patients 1 -5; therefore, the proviral DNA level reductions we observed in these patients seem to reflect a reduction in the number of CD4 T lymphocytes infected productively.
HIV-1 is a blood-borne virus, as are human T lymphotropic virus type 1, 15 hepatitis B virus 16 and hepatitis C virus, 17 all of which are associated with viral mutations within individuals. The deduced amino-acid variation frequency in the gag region of our patients following anti-retroviral treatment was 0.20 -4.76%, similar to results observed in HIV-1-positive patients without treatment (0.79 -2.97%). 18 A period with a high rate of mutation in the gag region was seen while one patient underwent treatment for hepatitis C virus with interferon-β in our study. In all cases, HIV-1 in the gag region is not as conserved in individual carriers as human T-cell lymphotropic virus (HTLV-1) is (0 -0.24%), although this is also a retrovirus. 14 Marked reductions were seen in HIV-1 proviral DNA levels of patients with HIV-1 mutations, including those in whom replacement of the major clone was observed.
Viral variations reported in HIV-1-infected infants have indicated that those with limited viral evolution experience rapid disease progression. 19 The serial cloning and sequencing examinations in the present study revealed genomic change and shifts in the population of clones (and major clone reductions), and reductions in HIV-1 RNA and proviral DNA levels were mapped in detail. Our results suggest that changes in major clones were related to changes in sera HIV-1 RNA levels and CD4 T lymphocyte counts. Changes in HIV-1 proviral DNA levels were small, but by cloning and sequencing the gag region, HIV-1 quasispecies changes became clear. In contrast, in patients 6 -11, HIV-1 RNA levels did not become undetectable and major increases in clone numbers were observed. A reduction in HIV-1 proviral DNA levels appears to be associated with reductions in the number of major clones found in the gag region. Specific amino-acid substitutions in the pol region, which encodes reverse transcriptase and protease inhibitors and results in drug resistance, have been reported. 20 -22 Further tests and comparisons of viral mutations in these patients, using anti-retroviral drugs, are necessary.
Perrin et al. 23 reported that HIV-1 proviral DNA levels in patients with acute HIV-1 infection were reduced to undetectable by antiretroviral treatment, as were serum HIV-1 RNA levels. Our patient with primary HIV-1 infection had a rapid reduction in HIV-1 RNA I Ariyama, Y Chong, M Murata et al. The effectiveness of HIV-1 anti-retroviral therapy and a remarkable reduction of HIV-1 proviral DNA level in PBMCs following HAART, contrary to the results observed in chronically infected patients. Such treatment at the primary stage of HIV-1 infection might control viraemia efficiently, and the loss of HIV-1-specific CD4 T-lymphocyte responses has been suggested by others. 24 -26 Many physicians question when HAART should be undertaken in patients in the primary stage of HIV-1 infection. Multiple anti-retroviral drugs combinations are long-term therapeutic strategies that are associated with sideeffects, toxicity and therapeutic failure due to the potency of the drugs used. However, our results, which have been obtained from proviral DNA in PBMCs, indicate that if HIV-1 RNA is reduced to undetectable levels by HAART, HIV-1 proviral DNA levels also reduce. The population of major clones seems to be related to the reduction in HIV-1 RNA levels following HAART. 
